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Due to their inherent biodegradability and biocompatibility, lipids are now being
extensively investigated as carriers (1) for drugs and proteins. Most research is focused
on the development of lipid based delivery systems over polymeric carriers. Several
workers have reported the cellular toxicity (2, 3) of monomers after intracellular process-
ing of polymeric carriers.
Lipospheres comprise a lipid core with surface coated emulsifier molecules, with
the drug dissolved or dispersed in it. Lipospheres have been exploited for the delivery
of anesthetics (4, 5), antibiotics (6) and antifungal agents (7), for parenteral delivery of
vaccines and adjuvants, for transdermal (8) and oral delivery (9). Lipospheres can be
prepared by melt dispersion, solvent evaporation, microemulsion and multiple emul-
sion methods (10).
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Fenofibrate lipospheres were prepared by the melt dis-
persion technique. Critical parameters influencing parti-
cle size and entrapment efficiency were optimized by ap-
plying the L9 Taguchi experimental design. Entrapment
efficiency of up to 87 % was obtained for the optimized
formulation on increasing olive oil up to 30 % in the
lipid carrier. Particle size analysis by microscopy and
SEM revealed narrow particle size distribution and for-
mation of discrete lipospheres of superior morphology.
In vitro dissolution data best fitted the Higuchi model,
indicating diffusion controlled release from porous lipid
matrices. Prolonged release was obtained from stearic
acid-olive oil lipospheres compared to cetyl alcohol-olive
oil lipospheres due to the relatively hydrophobic matrix
formed by stearic acid. Lipid lowering studies in Triton
induced hyperlipidemia rat model demonstrated higher li-
pid lowering ability for fenofibrate lipospheres compar-
ed to the commercial product and plain drug.
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Fenofibrate, a BCS class II compound has been chosen as a model drug molecule to
investigate the potential of lipospheres in enhancing its oral bioavailability. Oils used in
the present work have been selected so as to provide an adjuvant effect on the drug due
their ability to enhance high density lipids and lower the plasma triglyceride and chole-
sterol levels apart from formulation considerations. Fenofibrate is commercially avail-
able as micronized powder in the form of oral tablets and capsules (Trilipix®, Lipofen®,
Antara®, Lipicard®). However, micronization is a time and energy consuming process
and comicronization of fenofibrate with surfactants such as sodium lauryl sulfate (Lipi-
dil micro®) causes mucosal irritation. Hence the current research work investigates lipo-
spheres formulated with safer excipients as carriers for fenofibrate to overcome the limi-
tations of marketed products.
EXPERIMENTAL
Materials
Fenofibrate (unmicronized) was a gift from Alembic Limited, India. Phospholipon
90H and Phospholipin 80H were kindly provided by Lipoid GmBH (Germany). Stearic
acid, cetyl alcohol, soy lecithin, sodium lauryl sulphate were purchased from S.D. Fine
Chemicals Limited (India). Olive oil was purchased from Sos Cuetara (Spain). Sunflower
oil was purchased from Sarawwalaa Agro Refineries Limited (India). Triton WR 1339
(Tyloxapol) was purchased from Sigma Chemical Co (USA). Marketed formulation Lipi-
card 200 mg capsules containing micronized fenofibrate from USV Ltd. (India) and were
used to compare the performance of liposphere formulations.
Preparation of fenofibrate lipospheres by the melt dispersion technique
Melted lipid mixture containing the lipophilic model drug was emulsified into an
external aqueous phase containing a suitable surfactant kept at the same temperature as
the lipid phase. The emulsion was mechanically stirred with a stirrer equipped with al-
ternative impellers. The milky formulation was then rapidly cooled by immersing the
formulation flask in a cool water bath without stopping the agitation to yield a uniform
dispersion of lipospheres. The obtained lipospheres were then washed with water and
isolated by filtration through a Whatman filter paper. Blank lipospheres (without drug)
were prepared by the same method.
Determination of entrapment efficiency
Lipospheres (50 mg) were accurately weighed into centrifuge tubes to which sodium
lauryl sulphate (SLS) medium (0.1 mol L–1, 10 mL) was added. The preparations were
centrifuged at 10,000 g at 4 °C for 30 min. The pellets obtained upon filtering the centri-
fuged preparation were washed again with 10 mL of 0.1 mol L–1 SLS and re-centrifuged
under the same conditions for 30 min. The filtrates from two centrifugation cycles were
analyzed for un-entrapped drug.
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Decanted lipospheres from the above step were dissolved in 10 mL of methanol and
the preparation was sonicated for 15 min to obtain a clear solution. The resulting solu-
tion, after appropriate dilution, was analyzed spectrophotometrically at 291 nm using a
UV 2600 spectrophotometer (Chemito Instruments Pvt. Ltd., India) for the amount of
fenofibrate entrapped in the lipospheres.
Determination of partition coefficient by the shake-flask method
The solvent system comprising octanol (100 mL) and 100 mL of water was shaken
vigorously in a separating funnel for half an hour to saturate solvent layers with one an-
other. Accurately weighed amount of 100 mg of the drug or formulation containing an
equivalent amount was added and the mixtures were shaken vigorously for 30 min to al-
low drug distribution between the two immiscible phases and then both organic and
aqueous layers were separated. Concentration of fenofibrate present in aqueous and or-
ganic layers was determined spectrophotometrically. The partition coefficient was calcu-
lated.
Particle size and surface morphology
Approximately 1 mg of liposphere formulation was mounted on a glass slide and
the sample was covered with a coverslip. The mounted sample was observed under an
optical microscope (Digi 3 Labomed, The New York Microscope Company, USA) using a
calibrated eye piece under 45 magnification.
Morphological examination of the surface of the optimized fenofibrate formulation
was carried out with a scanning electron microscope (JEOL JSM-6100, Japan). The parti-
cles were vacuum dried, coated with a thin gold-palladium layer with a sputter coater
unit and observed microscopically at an accelerating voltage of 5.0 kV.
Fourier transform infrared (FTIR) spectroscopy
FTIR spectra of pure fenofibrate and the optimized liposphere formulation were re-
corded with a FTIR spectrophotometer (FTIR-Shimadzu 8400 S, Japan) from 4000–400
cm–1 using KBr pellets. The pellets were made by applying a pressure of 100 kg cm–2 to a
mixture of lipids and KBr (1:20) for 10 min in a hydraulic press (KP, Kimaya Engineers,
India).
Differential scanning calorimetry
DSC thermograms of fenofibrate, placebo lipospheres and optimized drug loaded
lipospheres were recorded using a Shimadzu instrument (model TA-50 WSI, Japan) cali-
brated with indium. The analysis was carried out on 3.5-mg samples sealed in standard
aluminum pans. Thermograms were obtained under dry nitrogen flow (25 mL min–1)
between zero and 400 °C at a scanning rate of 10 °C min–1.
In vitro release of fenofibrate from lipospheres
Lipospheres or a marketed product equivalent to 50 mg of fenofibrate were accura-
tely weighed and filled into gelatin capsules. Degassed 0.1 mol L–1 SLS medium (900 mL)
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was placed into the dissolution tester jars and the temperature was maintained at 37 ± 2 °C.
A USP II dissolution apparatus at 75 rpm (11) was used. Samples of 5 mL were drawn at
time points of 30, 45, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 and 360 min and an
equal amount of fresh dissolution medium was replaced each time. Samples were ana-
lyzed spectrophotometrically at 291 nm (12).
The release data was subjected to kinetic treatment by zero-order (cumulative per-
centage drug release vs. time), first-order (log cumulative percentage drug released vs.
time), Higuchi model (cumulative % drug release vs. square root of time) (13) to deter-
mine the release mechanism. Determination coefficients (R2) were calculated for all the
formulations. Release exponent n was calculated from the Korsmeyer-Peppas equation
(14) (log cumulative % drug release vs. log time).
Lipid lowering study
Approval to carry out these studies was obtained from the Institutional Animal Ethics
Committee (IAEC) (320/CPCSEA) of the G. Pulla Reddy College of Pharmacy, Hyderabad,
India.
Male Wistar rats (250 ± 30 g) were kept in air-conditioned rooms (24–25 °C) with
constant humidity. Rats starved for 18 hours were given intraperitoneal injection of Tri-
ton WR 1339 dissolved in 0.9 percent saline at a dose of 250 mg kg–1 to induce hyperlipi-
demia within 24 h. Control groups of rats were given the vehicle (plain saline) and ex-
perimental groups were given plain fenofibrate (9 mg kg-1 body mass) or the liposphere
formulation (equivalent to 9 mg kg–1 fenofibrate) or the marketed product Lipicard
(fenofibrate, 200 mg) capsules (equivalent to 9 mg kg–1 fenofibrate). Without anesthesia
and restraining rats by hand, the oral dosing was performed by intubation using an
18-gauge feeding needle (the volume to be fed was 1.0 mL in all cases). To study the
effect of formulation components on lipid lowering, one more group was included; this
group was fed a placebo formulation. Blood samples were drawn at 0, 24 and 48 hours.
Serum was separated by centrifugation at 10000 g and used for biochemical analysis. Se-
rum cholesterol was estimated by the modified Roeschlau’s method (15) and triglycer-
ides were estimated by McGowan et al. and Fossati et al. (16) method using a standard
kit obtained from ERBA diagnostics (Germany). Statistical analysis of the collected data
was performed using t-test (unpaired, one-tailed) to test whether there was a significant
difference between treated and control groups.
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Table I. Variables and levels used for the Taguchi L9 orthogonal array









B Lipid ratio 90:10 80:20 70:30
C Type of emulsifier PL90H PL80H Soy lecithin (SL)
D Content of emulsifier (%) 5 10 15
Orthogonal array and Taguchi experimental design
Taguchi method (17) is a combination of mathematical and statistical techniques used
in an empirical study. It determines the experimental conditions having least variability
as the optimum condition. The variability of a property is due to the »noise factor«. On
the other hand, a factor easy to control is called the »control factor«. Variability can be
expressed by the signal-to-noise ratio. The experimental condition having the maximum
S/N ratio is considered the optimum condition, as the variability of characteristics is in
inverse proportion to the S/N ratio.
Variables and levels were taken as denoted in Table I. The signal-to-noise (S/N) ra-
tio was calculated for each factor level combination. S/N response for »larger is the
better option« was considered. The formula for the larger-is-better S/N ratio is
S/N = –10 log(S(1/Y2)/n)
where Y is the response for the given factor level combination and n is the number of re-
sponses in the factor level combination. L9 orthogonal array used in the present study is
represented in Table II.
RESULTS AND DISCUSSION
Optimization of entrapment efficiency and yield from Taguchi experimental runs
The objective of the present experiment is to apply the Taguchi L9 orthogonal de-
sign for optimizing liposphere properties and thereby to arrive at an optimum formula,
giving lipospheres with high yield, narrow particle size distribution and higher entrap-
ment efficiency.
It was observed in preliminary trials that a lipid/drug ratio of a minimum of 10:1
was required to obtain high entrapment efficiency. Hence, Taguchi experimental runs
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Fig. 1. Main effect plot of the S/N ratio for entrapment efficiency.
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were done at this ratio. S/N ratios for output parameters, namely, entrapment efficiency
and yield, were calculated. Results are shown in Table II.
The formula showing highest entrapment efficiency (OF1) of 89.9 % was found to be
A1, B1, C1, D2, corresponding to stearic acid/olive oil, 90:10, phospholipon 90H, 10 %,
respectively (Fig. 1).
The optimum formula for yield (OF2) was found to be A2, B1, C1, D2, correspond-
ing to cetyl alcohol/olive oil, 90:10, phospholipon 90H, 10 %, respectively.
Factors influencing entrapment efficiency
Lipid/oil ratio. – At a constant phospholipid amount, the lipid core formulated with
stearic acid alone (without vegetable oils) gave lipospheres of highest entrapment effi-
ciency. As the amount of oil in the lipid core increased, the entrapment efficiency de-
creased. This observation is contrary to the concept of nanolipid carriers (18), which in
theory should increase loadability of the drug due to the formation of an asymmetric
lipid structure providing more room for drug loading. The decrease in entrapment ef-
ficiency of the fenofibrate liposphere formulation containing oils was probably due to
the limiting and competing solubility of oil and lipophilic drug (fenofibrate) in the solid
lipid. Olive oil (rich in monounsaturated fatty acids, MUFA) based lipospheres showed
higher drug entrapment compared to sunflower oil (rich in polyunsaturated fatty acids,
PUFA) based lipospheres due to higher solubility of MUFA in saturated fat (stearic acid)
which provides more room for drug loading compared to PUFA (19).
Type of phospholipid. – Entrapment efficiency of fenofibrate was found to increase in
lipospheres formulated with synthetic emulsifiers like Phospholipon 90H and 80H com-
pared to the natural emulsifier used (soy lecithin). This was probably due to the report-
ed leaky nature of phospholipid membranes formed by natural phospholipids compar-
ed to synthetic lipids.
Partition coefficient
A drastic reduction in the partition coefficient of the drug entrapped in lipospheres
was observed (log P ranging from 0.7–1.3) compared to the drug itself (log P of
fenofibrate is 5.3). This effective reduction of the log P value indicates improved parti-
tioning of the drug from the formulation into aqueous phase, which is attributed to an
increase in the amount of emulsifier. Results are presented in Table II.
Particle size
From Table II it is evident that the combination of stearic acid and olive oil with the
highest amount (15 %) of emulsifier gave the smallest particles, as demonstrated by trial
T3. Among all the emulsifiers used, soy lecithin resulted in the smallest particle size but
the lipospheres were found to be aggregated when observed under microscope. As the
lipid/oil ratio increased, the particle size of lipospheres in Taguchi trials (T4, T7) decreas-
ed. This decrease in particle size was probably due to the availability of higher amounts
of carrier material and emulsifier for the formation of discrete spherical particles.
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Fig. 2 shows the scanning electron microscopic image of fenofibrate lipospheres,
which substantiates the formation of discrete particles of 100 µm with smooth surfaces.
Optimized fenofibrate formulation was prepared at three different stirring speeds,
namely 750, 1500 and 2500 rpm (data not shown). A drastic reduction in particle size was
observed when the stirring speed of 1500 rpm was used, resulting in a particle size of
60–75 µm when compared to the stirring speed of 750 rpm (180 µm). Decrease in particle
size was only minimal when the stirring speed was changed from 1500 rpm (60–75 µm)
to 2500 rpm (30–45 µm). This result is in accord with the fact that the particle size de-
creases linearly with an increase in stirring speed up to a particular value, after which
the relationship between particle size and stirring speed becomes nonlinear.
Drug-lipid compatibility
Drug-lipid compatibility in optimized lipospheres was evaluated by FTIR and DSC
analysis. FTIR spectra are displayed in Fig. 3. The principal peaks of fenofibrate were ob-
served between 600–800 cm–1; they resulted from C-Cl stretching. The peaks at 1729.4,
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Fig 2. SEM image of fenolfibrate lipospheres.
Fig. 3. FTIR spectrum of a) pure drug, b) excipients, c) physical mixture of drug and excipients of
OF1 formulation.
1651.0, 1598.9 and 925.1 cm–1 correspond to C=O, C=C stretching of the carboxylate group
and C-H bending, respectively. These characteristic peaks were identified in a physical
mixture of the drug and excipients with no appreciable changes in frequency. Thus, it
can be inferred that there was no chemical interaction between the drug and lipids used
in the formulation.
DSC thermogram of fenofibrate showed an endothermic peak at 82 oC, which is within
the melting range of the drug (Fig. 4a). DSC thermogram of pure stearic acid showed an
endothermic peak at 54.13 oC, which is the reported melting point of stearic acid. Plain
lipospheres prepared by the melt dispersion method showed an endothermic peak at
51.38 °C and a small exotherm at 64.46 °C. Drug loaded lipospheres prepared by the
same method showed a large endothermic peak at 49.53 oC and disappearance of the
drug peak (Fig. 4b), suggesting that the drug is present in form of molecular dispersion
in the loaded lipospheres and that fenofibrate exists in amorphous state rather than in
crystalline state. Also, the melting point for stearic acid decreased from 54.13 to 51.38 °C
and 49.53 °C for plain and drug loaded lipospheres, respectively, which could be attrib-
uted to the smaller size of prepared lipospheres. Also, the inclusion of drug molecules in
the lipid is normally accompanied by a depression in the melting point of the lipid.
In vitro release
It was observed in the in vitro release study that OF1 (stearic acid and olive oil lipo-
spheres) extended the release of the drug for up to 5 h whereas OF2 (cetyl alcohol and
olive oil lipospheres) gave immediate release of the drug similar to the marketed for-
mulation containing fenofibrate in micronized form (Fig. 5). This is probably due to the
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Fig. 4. DSC thermogram of: a) fenofibrate (pure drug), b) formulation (OF1).
a)
b)
higher affinity of alcohol groups towards the dissolution medium promoting matrix hy-
dration, which provides a hydrophilic pathway for water molecules to solubilize the drug,
thus leading to an increase in dissolution rate. Owing to the crystalline nature of the li-
pid matrix formed due to interaction of stearic acid with sodium ions in SLS medium,
drug solubility and hence release are assumed to be retarded (20).
Release profiles of Taguchi experimental runs were fitted into zero-order, first-order
and Higuchi models (13) to determine release kinetics and the mechanism of drug re-
lease. Regression coefficient values from Table III clearly indicate that the data best fitted
the Higuchi model, indicating diffusion controlled release from porous lipid matrices.
To characterize the diffusional release, the Korsmeyer-Peppas model (14) was applied.
Since the release component value n for the majority of Taguchi runs is between 0.5 and
1.0 indicating anomalous release, both diffusion and dissolution from polymer matrix
appear to govern the drug release (21).
Lipid lowering studies
Table IV shows the serum cholesterol and triglyceride levels at 0, 24 and 48 h. A
drastic increase in serum cholesterol and triglyceride levels after 24 h indicates induc-
tion of hyperlipidemia in male Wistar rats due to Triton treatment. However, after treat-
ment with the plain drug, marketed product (Lipicard®) and fenofibrate lipospheres
(OF1) to respective groups at 9 mg kg–1 orally, the liposphere formulation demonstrated
the highest lipid (cholesterol and triglycerides) lowering. In vivo studies indicated that
the lowering of serum cholesterol and triglycerides by the liposphere formulation was
comparable to that of the marketed product. Significant difference between Triton control
vs. fenofibrate lipospheres (OF1)/marketed formulation was obtained at 24 and 48 h, es-
pecially for triglyceride levels compared to cholesterol levels. This is in accord with the
fact that the fibrate class of drugs mainly act by lowering the triglyceride levels. No sig-
nificant difference between the control and plain drug was observed due to the drug
poor bioavailability.
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Fig. 5. Comparative in vitro release profiles of: pure drug, Lipicard and OF1 (stearic acid:olive oil,
90:10, phospholipon 90H, 10 % showing sustained release). Mean ± SD, n = 3.
CONCLUSIONS
Fenofibrate containing lipospheres were prepared by hot emulsification and cold
re-solidification of a mixture of lipids and oils. Lipid/oil ratio was found to play an im-
portant role in the formation of discrete lipospheres and in drug entrapment. About
85 % of the drug was found to be entrapped at 10 % of oil in lipid in the optimized for-
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Table III. Release kinetics of fenofibrate lipospheres
Formu-
lation





R2 k0 (% min
–1)a R2 k1 (min
–1)a R2 kH (% min
–1/2)a nb
T1 0.911 0.256 0.819 0.001 0.971 6.338 0.603 Anomalous
T2 0.979 0.224 0.885 0.001 0.986 5.389 0.595 Anomalous
T3 0.974 0.270 0.882 0.002 0.999 6.049 0.599 Anomalous
T4 0.991 0.333 0.980 0.002 0.999 6.674 0.592 Anomalous
T5 0.960 0.261 0.820 0.003 0.987 5.855 0.993 Anomalous
T6 0.982 0.325 0.936 0.002 0.986 7.630 0.761 Anomalous
T7 0.975 0.280 0.879 0.002 0.998 6.266 0.694 Anomalous
T8 0.926 0.100 0.890 0.032 0.970 2.469 0.166 Fickian
diffusion
T9 0.948 0.193 0.924 0.001 0.977 3.494 0.203 Fickian
diffusion
a k0, k1 and kH – release rate constants for zero-order, first-order and Higuchi model, respectively; b Release exponent.
Table IV. Treatment of serum cholesterol and triglyceride levels in vivo
Treatment group Cholesterol (mg per 100 mL) Triglycerides (mg per 100 mL)
Initial 24 h 48 h Initial 24 h 48 h
Normal control 236.7 ± 5.6 238.9 ± 4.5 235.7 ± 6.4 180.5 ± 7.3 188.4 ± 8.9 184.9 ± 10.3
Triton control 236.7 ± 6.8 540.4 ± 5.2 549.8 ± 5.9 178.9 ± 11.8 332.0 ± 9.2 322.0 ± 5.4
Placebo 235.8 ± 5.8 580.0 ± 7.2 575.9 ± 4.1 165.6 ± 10.8 350.2 ± 8.7 360.5 ± 5.4
Plain drug 230.8 ± 10.4 642.8 ± 5.9 486.1 ± 12.3 200.2 ± 8.2 379.8 ± 7.1 288.4 ± 4.8
Marketed product
(Lipicard)
230.6 ± 8.6 683.4 ± 9.3 53.5 ± 6.2 188.7 ± 9.9 414.0 ± 4.8a 139.0 ± 10.6a
Fenofibrate
lipospheres
222.1 ± 4.3 663.0 ± 5.9a 33.7 ± 7.3a 163.5 ± 3.7 375.0 ± 6.9a 130.9 ± 2.5a
Mean ± SD, n = 6. a Indicates statistically significant difference between treated group and Triton control at
p < 0.002.
mulation, OF1. However, entrapment efficiency was found to decrease with an increase
in the amount of oil in the lipid carrier. Drug release from lipospheres varied from
prolonged release shown by OF1 (stearic acid and olive oil lipospheres) to immediate re-
lease shown by OF2 (cetyl alcohol and olive oil lipospheres), indicating the role of the
lipid type in altering drug release. In vivo studies in male Wistar rats indicated that OF1
demonstrated a lowering of serum cholesterol levels in comparison with the marketed
product. It can be concluded from these results that the liposphere formulation can be
exploited as a novel drug delivery system for poorly soluble drugs like fenofibrate as
these lipospheres can be prepared by using easily available, inexpensive, GRAS listed
excipients and simple preparation techniques resulting in bioavailable fenofibrate for-
mulations.
REFERENCES
1. G. Fricker, T. Kromp, A. Wendel, A. Blume, J. Zirkel, H. Rebmann, C. Setzer, R. O. Quinkert, F.
Martin and C. M. Goymann, Phospholipids and lipid-based formulations in oral drug delivery,
Pharm. Res. 27 (2010) 1469–1486; DOI: 10.1007/s11095-010-0130-x.
2. Y. C. Tseng, Y. Tabata, S. H. Hyon and Y. Ikada, In vitro toxicity test of 2 cyanoacrylate polymers
by cell culture method, J. Biomed. Mater. Res. A 24 (1990) 1355–1367; DOI: 10.1002/jbm.820241007.
3. K. Lam, J. Schakenraad, H. Esselbrugge, J. Feijen and P. Nieuwenhuis, The effect of phagocyto-
sis of poly(L -lactic acid) fragments on cellular morphology and viability, J. Biomed. Mater. Res. A
27 (1993) 1569–1577; DOI: 10.1002/jbm.820271214.
4. D. B. Masters and A. J. Domb, Liposphere local anesthetic timed-release for perineural site
application, Pharm. Res. 15 (1998) 1038–1045; DOI: 10.1023/A:1011978010724.
5. S. Toongsuwan, L. C. Li, B. K. Erickson and H. C. Chang, Formulation and characterization of
bupivacaine lipospheres, Int. J. Pharm. 280 (2004) 57–65; DOI: 10.1016/j.bbr.2011.03.031.
6. A. J. Domb, Long acting injectable oxytetracycline-liposphere formulations, Int. J. Pharm. 124
(1995) 271–278; DOI: 10.1016/0378-5173(95)00098-4.
7. B. Amarji, D. Raghuwanshi, S. Vyas and P. Kanaujia, Lipid nano spheres (LNSs) for enhanced
oral bioavailability of amphotericin B: development and characterization, J. Biomed. Nanotech-
nol. 3 (2007) 264–269; DOI: 10.1166/jbn.2007.029.
8. A. Bhatia, B. Singh, V. Rani and O. Katare, Formulation, characterization, and evaluation of ben-
zocaine phospholipid-tagged lipospheres for topical application, J. Biomed. Nanotechnol. 3 (2007)
81–89; DOI: 10.1166/jbn.2007.009.
9. T. Bekerman, J. Golenser and A. Domb, Cyclosporin nanoparticulate lipospheres for oral ad-
ministration, J. Pharm. Sci. 93 (2004) 1264–1270; DOI: 10.1002/jps.20057.
10. N. Sateeshbabu and K. Gowthamarajan, Manufacturing techniques of lipospheres: overview, Int.
J. Pharm. Pharm. Sci. 3 (2011) 17–21.
11. United States Pharmacopoeia XXXI, National Formulary XXVI, USP Convention, Rockville (MD)
2008, pp. 2145–2146.
12. J. J. Sheng, P. J. Sirois, J. B. Dressman and G. L. Amidon, Particle diffusional layer thickness in a
USP dissolution apparatus II: a combined function of particle size and paddle speed, J. Pharm.
Sci. 97 (2008) 4815–4829; DOI: 10.1002/jps.21345.
13. T. Higuchi, Mechanisms of sustained action medications: theoretical analysis of rate of release
of solid drugs dispersed in solid matrices, J. Pharm. Sci. 52 (1963) 1145–1149; DOI: 10.1002/jps.
2600521210.
82
Ch. Saroja and P. K. Lakshmi: Formulation and optimization of fenofibrate lipospheres using Taguchi’s experimental design, Acta
Pharm. 63 (2013) 71–83.
14. R. W. Korsmeyer, R. Gurny, E. Doelker, P. Buri and N. A. Peppas, Mechanisms of solute release
from porous hydrophilic polymers, Int. J. Pharm. 15 (1983) 25–35; DOI: 10.1016/0378-5173(83)
90064-9.
15. P. Röeschlau, E. Bernt and W. Gruber, Enzymatic determination of total cholesterol in serum,
Z. Klin. Chem. Klin. Biochem. 12 (1974) 403–407.
16. P. Fossati and L. Prencipe, Serum triglycerides determined colorimetrically with an enzyme that
produces hydrogen peroxide, Clin. Chem. 28 (1982) 2077–2080.
17. K. D. Kim, D. N. Han and H. T Kim, Optimization of experimental conditions based on the
Taguchi robust design for the formation of nano-sized silver particles by chemical reduction
method, Chem. Eng. J. 104 (2004) 55–61; DOI: 10.1016/j.cej.2004.08.003.
18. L. Mu and S. S. Feng, Fabrication, characterization and in vitro release of paclitaxel (Taxol®) loaded
poly(lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/choleste-
rol emulsifiers, J. Control. Release 76 (2001) 239–254; DOI: 10.1016/S0168-3659(01)00440-0.
19. A. Dubey, P. Prabhu and J. V. Kamath, Nano structured lipid carriers: A novel topical drug de-
livery system, Int. J. Pharm. Tech. Res. 4 (2012) 705–714.
20. M. Nasr, S. Mansour, N. D. Mortada and A. El. Shamy, Lipospheres as carriers for topical deliv-
ery of aceclofenac: Preparation, characterization and in vivo evaluation, AAPS PharmSciTech. 9
(2008) 154–162; DOI: 10.1208/s12249-007-9028-2.
21. M. Ozyazici, E. H. Gokçe and G. Ertan, Release and diffusional modeling of metronidazole li-
pidmatrices, Eur. J. Pharm. Biopharm. 63 (2006) 331–339; DOI: 10.1016/j.ejpb.2006.02.005.
83
Ch. Saroja and P. K. Lakshmi: Formulation and optimization of fenofibrate lipospheres using Taguchi’s experimental design, Acta
Pharm. 63 (2013) 71–83.

